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Purpose: One hundred twenty patients undergoing aortic reconstruction (40), infrain- 
guinal bypass (49), and carotid endarterectomy (31) were prospectively enrolled into a 
double-blind randomized trial to investigate the utility of routine heparin reversal with 
protamine. 
Methods: All patients underwent systemic heparinization with 90 U/kg body weight during 
operation and after revascularization were randomized to receive either protamine or 
saline solution for heparin reversal. Blood loss was measured throughout the surgical 
procedure, and indexes of coagulation and the requirement for blood and blood products 
were documented during operation a d the first 24 hours after operation. 
Results: Plasma heparin concentration, partial thromboplastin time, and activated clotting 
time were significantly higher (p < 0.05) in those receiving saline solution at 20 minutes 
and 1 hour after administration. Total surgical blood loss was not significantly different 
between study groups. No significant differences were found in blood product require- 
ment, intravenous fluid administered, hematocrit, or wound hematomas between groups 
at 24 hours. In addition, no difference was seen in the surgeon's ubjective intraoperative 
assessment of hemostasis after administration of either study drug. Furthermore, after 
study drug administration protamine was associated with a deleterious effect on 
subsequent intraoperative blood loss (318 + 33 ml vs 195 + 18 ml, p < 0.05). 
Conclusions: Although protamine ffectively reverses heparin anticoagulation, ts routine 
use after elective peripheral vascular surgical reconstruction does not appear to provide any 
clinical benefit. (J VAsc SvRa 1995;22:248-56.) 
Protamine is widely used for reversal of systemic 
heparin anticoagulation.i Several types of deleterious 
protamine reactions have been shown to occur after 
intravenous administration, including peripheral va- 
sodilatation from histamine release, reductions in 
myocardial contractility, and increased pulmonary 
artery and venous pressure resulting from thrombox- 
ane release and sludging of blood components. 29 
Other adverse effects of protamine can affect the 
coagulation system and include inhibition of platelet 
aggregation, a reduction in platelet number, and 
From the Department of Anesthesiology and the Department of 
Surgery (Drs. Elliott, Spinale, Robinson, and Brothers) Medical 
University of South Carolina, Charleston. 
Presented at the Nineteenth Annual Meeting of the Southern 
Association for Vascular Surgery, Canctln, Mexico, Jan. 25-28, 
1995. 
Reprint requests: B. Hugh Dorman, PhD, MD, Department of 
Anesthesiology, Medical University of South Carolina, 171 
Ashley Ave., Charleston, SC29425-2207. 
Copyright © 1995 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/95/$5.00 + 0 24/6/65665 
248 
prolongation of prothrombin and partial thrombo- 
plastin times. I°-13 The most serious reaction to 
protamine is anaphylaxis, characterized by circulatory 
shock, severe bronchospasm, and occasionally cardiac 
arrest. 14a5 Anaphylaxis is more common in patients 
with previous sensitization to protamine, chronic 
exposure to neutral protamine Hagedorn insulin, 
documented shellfish allergy, or after vasectomy. 16,17 
Many patients presenting for a peripheral vascular 
surgical procedure are included in this high-risk 
group. It is not clear that patients undergoing a 
peripheral vascular operation require protamine neu- 
tralization of heparin, because the initial dose of 
heparin is relatively low, and heparin is cleared from 
the plasma with a half-life at normothermia that 
ranges from 90 to 120 minutes. TM The decision to 
administer protamine during a peripheral vascular 
surgical procedure is often based on personal expe- 
rience or the perceived rate of bleeding at the 
operative site, both very subjective parameters. In 
light of the pharmacokinetics of heparin and the 
overall heparin dose administered in peripheral 
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vascular operations, we hypothesized that protamine 
administration would not improve objective mea- 
sures of blood loss in this particular clinical setting. 
Accordingly, the overall objective of this study was to 
compare clinical and laboratory assessments of he- 
mostasis between patients in whom protamine neu- 
tralization of heparin was accomplished or not to 
determine whether protamine is required in periph- 
eral vascular operations. 
MATER[iAL AND METHODS 
After approval by the Human Subjects Review 
Committee of the Medical University of South 
Carolina was obtained, informed consent for the 
study was obtained from 120 patients undergoing 
peripheral vascular operation. Only patients under- 
going major elective peripheral vascular surgical 
procedures were included; these procedures con- 
sisted of abdominal aortic aneurysm repair (AAA), 
carotid endarterectomy (CEA), and infrainguinal 
bypass (IIB). Patients were prospectively randomized 
in a double-blind fashion to receive ither protamine 
(protamine group) or saline solution (saline solution 
group) for reversal of heparin effect. Patients were 
excluded from the study by any of the following 
criteria: preoperative abnormalities in coagulation 
status (n = 10), documented allergy to protamine by 
history (n = 1), or the development ofunexplained 
hemodynamic instability before the administration f 
study drug, protamine, or saline solution (n = 1). 
On the evening before the operation, serum 
chemistries, liver function tests, hematocrit (Hct), 
hemoglobin, and a standard coagulation profile were 
obtained, which consisted of platelet count, fibrino- 
gen level, prothrombin time (PT), and partial throm- 
boplastin time (PTT). Just before induction, a sample 
of blood was removed from a peripheral artery for 
baseline activated clotting time (ACT). A combined 
right ventricular ejection fraction, oximetry, ther- 
modilution pulmonary artery catheter (7.5F, Baxter 
Healthcare, Irvine, Calif.) was placed in the right 
internal jugular vein in all patients undergoing AAA; 
patients undergoing CEA and IIB received a pulmo- 
nary artery catheter only if deemed necessary by the 
anesthesiologist for patient care. The output from the 
thermistor and the analog electrocardiogram signal 
were interfaced to a thermodilution ejection fraction 
computer (Monarch REF-1, Baxter Healthcare). 
With this catheter and computer system, right 
ventricular ejection fraction (RVEF), cardiac output 
(CO), and right ventricular end diastolic volume 
(RVEDV) were computed from the thermodilution 
curve as described previously. 19
On request by the surgeon for heparin, abaseline 
sample of blood for plasma heparin concentration 
(Medtronics Hemotec, FI/VlS, Minneapolis, Minn.) 
and ACT was obtained, and then 90 U/kg intrave- 
nous heparin was administered. Plasma heparin 
concentration a d ACT were repeated at 20 and 60 
minutes after heparin administration a d just before 
study drug (protamine or saline) administration. 
Study drug, requested by the surgeon on completion 
of vascular anastomosis, was administered in a 10 ml 
volume by steady intravenous infusion in a peripheral 
vein for 60 seconds. In those patients who received 
protamine as a study drug (protamine group), the 
dose of protamine was calculated from the plasma 
heparin concentration (units/ml) based on the esti- 
mated blood volume. ACT and plasma heparin 
concentration were again obtained 20 minutes after 
study drug administration a d every 60 minutes for 
up to 2 hours; once plasma heparin was not 
detectable or ACT returned to baseline values, 
additional measurements were not performed. 
In patients with pulmonary artery catheters, a 
complete hemodynamic profile was obtained just 
before study drug administration and consisted of 
mean arterial pressure (MAP), mean pulmonary 
artery pressure (PAP), PCWP, CO, RVEF, and 
RVEDV. Hemodynamic measurements were re- 
peated at 2-minute intervals for 10 minutes after 
study drug administration a d again at 20 minutes. 
Absolute blood loss was measured for the period 
from surgical incision to study drug administration 
and from study drug administration to the end of the 
surgical procedure. All sponges were weighed, and 
dry weight was subtracted out. The volume of blood 
collected in suction canisters and autotransfusion 
devices was determined, and the known volume of 
irrigation was subtracted. The volume of blood on 
surgical drapes was estimated from visual inspection 
and consistently contributed less than 10% of the 
total blood loss. Packed red blood cells were admin- 
istered for a Hct < 20% after all shed blood was 
autotransfused. Other blood products were admin- 
istered only in the setting of marked blood loss 
resulting from an apparent diffuse coagulopathy. If a 
clinical coagulopathy was documented, then blood 
products were administered bythe following criteria: 
platelets were given for a count of < 75,000/mm 3, 
cryoprecipitate was administered for a fibrinogen 
level < 100 mg/dl, and fresh-frozen plasma was 
infused with either PT or PTT > 1.5 times baseline 
value. 
A clinical assessment of coagulopathy was pro- 
vided by the surgeon just before and 20 minutes after 
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Table I. Patient characteristics and 
preoperative standard coagulation profile 
(mean __+ SEM) 
Saline solution s Protamine 7 ~ 
Weight (kg) 73 _+ 2 78 -+ 2 
Age (yr) 66 _+ 2 65 _+ 2 
Sex (m/f) 32/28 42/18 
Hematocrit (%) 39 -+ 1 38 + 1 
PT (sec)~z 11.6 _+ 0.1 12.4 _+ 0.5 
PTI'§ (sec) 28.7 _+ 0.6 29 _+ 0.7 
Fibrinogen (mg/dl) 381 _+ 13 365 -+ 22 
Platelet count ( x 103/ram 3) 257 _+ 10 257 + 13 
*Patient group that received saline for neutralization of heparin 
anticoagulation effect. 
?Patient group that received protamine for neutralization of 
heparin anticoagulation effect. 
:~Prothrombin time. 
§Partial thromboplastin time. 
study drug administration based on the degree of 
nonsurgical bleeding and the response to thrombin 
Gelfoam. Nonsurgical bleeding was classified into 
one of four categories: (1) dry, no detectable 
bleeding; (2) mild ooze, mild nonsurgical bleeding 
that responded to thrombin Gelfoam within 5 
minutes; (3) moderate ooze, moderate nonsurgical 
bleeding that responded tothrombin Gelfoam within 
10 minutes; (4) bloody, widespread, nonsurgical 
bleeding, not responsive to thrombin Gelfoam. 
At the conclusion of the surgical procedure Hct 
was repeated, and a standard coagulation profile was 
performed. The standard coagulation profile and Hct 
were repeated at 8, 16, and 24 hours after operation. 
Urine output, the volume of crystalloid and colloid 
infused, and the requirement for blood products 
during the operation and for the first 24 hours after 
the operation were documented. Patients underwent 
close follow-up for 3 days after the operation to 
document wound hematoma formation and reopera- 
don for bleeding or occluded vascular graft. 
All measurements collected in this study were 
coded with respect to drug treatment; the code was 
not broken until the study was completed. Compari- 
sons of patient demographic data and preoperative 
blood chemistry values were performed with a t test. 
Intraoperative and postoperative h modynamics and 
coagulation profiles were compared between the two 
study groups with an analysis of variance (ANOVA) 
for repeated measures. 2° If the analysis of variance 
revealed significant differences, pairwise comparison 
of group means was performed with Bonferroni's 
procedure. 21For discrete variables such as type of 
surgical procedure, sex, and surgeon's assessment of
the surgical field, multiway frequency tables were 
constructed and compared between the two groups 
with chi-squared analysis. All values are presented as 
Table II. Intraoperative blood loss (ml, 
mean _+ SEM) 
Saline solution Protamine 
Pre study drug s 750 -+ 98 897 -+ 104 
Post study drug? 195 _+ 18 318 _+ 331: 
Total§ 945 -+ 107 1215 + 123 
*The period that includes the start of the surgical procedure to 
study drug administration. 
?The period that includes tudy drug administration to the end of 
the surgical procedure. 
~;p < 0.05 vs saline solution group. 
§Total blood loss for the entire surgical procedure. 
mean _ standard error of the mean (SEM). Values 
ofp < 0.05 were considered statistically significant. 
RESULTS 
Sixty patients were enrolled in both the prot- 
amine group (protamine for heparin eutralization) 
and in the saline group (saline solution for heparin 
neutralization). The patient populations were similar 
in terms of age, sex, weight, liver function tests, 
serum chemistry values, American Society of Anes- 
thesiology Classification, preoperative electrocardio- 
graphic abnormalities, and preoperative coagulation 
status (Table I). Twenty-five percent of the patients 
were diabetic, accounting for 8% of patients under- 
going repair of AAA, 19% of patients undergoing 
CEA, and 43% of patients undergoing IIB. Total 
surgical duration (saline solutiongroup = 185 _ 13 
minutes and protamine group = 167 --+ 9 minutes), 
the period of time from the start of operation to study 
drug administration (saline solution group = 152 _+ 
12 minutes and protamine group = 131 _+ 8 min- 
utes), and the duration from study drug adminis- 
tration to the end of the surgical procedure (saline 
solution group = 34 + 2 minutes and protamine 
group = 35_  3 minutes) were similar between 
groups. Surgical procedures were equally distrib- 
uted; approximately the same number of patients in 
both groups underwent CEA (saline solution 
group = 18, protamine group = 13), repair of AAA 
(saline solution group = 17, protamine group = 
23), and lib (saline solution group = 24, protamine 
group = 25). 
Anesthetic technique was similar between pa- 
tients in the protamine and saline solution groups. 
Similar numbers of patients in either group received 
general anesthesia, lumbar epidurai or cervical plexus 
block, or a combination of general and regional 
anesthesia. Protamine dose for patients in the prot- 
amine group ranged from 15 to 81 mg with an 
overall average of 39.3 rag. Patients undergoing CEA 
averaged 44 mg protamine, whereas patients under- 
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Fig. 1. Perioperative heparin concentration. Changes in plasma heparin concentration 
throughout operation are illustrated for patients in both the saline solution and protamine 
groups. Plasma hcparin concentration remained significantly elevated uring operation over 
baseline, (pre-heparin values) for the entire 120 minutes measured after heparin administration 
in saline solution group. In contrast, plasma heparin was not detectable after study drug 
administration in protamine group. 
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Fig. 2. Perioperative activated clotting time (ACT). Changes in ACT throughout operation 
are illustrated for patients in both the saline solution and protamine groups. After heparin 
administration, i  saline solution group ACT remained significantly elevated over baseline 120 
minutes after study drug administration. At 20 minutes after study drug administration, ACT 
returned to baseline values in protamine group. 
going repair of AAA and IIB averaged 42 mg and 
34.4 rag, respectively. 
Total surgical blood loss was similar between 
patients treated with protamine or saline solution for 
reversal of heparin effect (Table II). A significant 
increase in blood loss was observed only after the 
administration fprotamine. In patients undergoing 
repair of AAA, total surgical blood loss (1309 +_ 168 
ml vs 1977 _+ 212 ml) and blood loss for the period 
after study drug administration (305 ± 33 ml vs 
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Table III. Subjective assessment 
of hemostasis 
Saline solution (%) Protamine 
Ire study drug 
Bloody ~ 13 28 
Moderate oozet 33 25 
Mild ooze~ 37 37 
Dry§ 17 10 
X 2 = 4.95,p = 0.175 
20 minutes post study drug 
Bloody 2 5 
Moderate ooze 8 17 
Mild ooze 45 32 
Dry 45 47 
X 2 = 4.076,p = 0.253 
~Widespread nonsurgical bleeding, not responsive to thrombin 
Gelfoam. 
~Moderate nonsurgical bleeding that responds to thrombin 
Gelfoam within 10 minutes. 
SMild nonsurgical bleeding that responds to thrombin Gelfoam 
within 5 minutes. 
§No detectable bleeding. 
489 _+ 49 ml) was also significantly greater in the 
protamine group. 
Plasma heparin concentration i creased signifi- 
cantly by a similar amount in both groups after 
intravenous heparin administration (Fig. 1). In the 
saline solution group, although a progressive decay in 
plasma heparin concentration ccurred throughout 
the surgical procedure, significantly elevated levels 
were still present 120 minutes after study drug 
administration. In the protamine group heparin 
concentration was significantly reduced to undetect- 
able levels at 20 minutes after study drug adminis- 
tration. ACT values after 90 U/kg heparin was 
administered increased tojust more than 270 seconds 
in both the saline solution and protamine groups and 
then showed similar reductions until study drug 
administration (Fig. 2). At 20 minutes after study 
drug administration, ACT was significantly reduced 
in the protamine group, having returned to baseline 
values. In the saline solution group the ACT re- 
mained significantly elevated over baseline values 120 
minutes after study drug administration. 
A clinical assessment ofhemostasis based on the 
degree of nonsurgical bleeding was provided by the 
surgeon just before and 20 minutes after study drug 
administration (Table III). The percentage of pa- 
tients in each group who were classified as having 
bloody ooze, moderate ooze, mild ooze, and dry ooze 
was similar between groups both before and after 
study drug administration. Furthermore the percent- 
age of patients noted to have worsened (42%) or 
improved (58%) coagulation status after study drug 
administration was identical between groups. 
Table IV. Blood product requirement 
through the perioperative p riod 
Saline solution Protamine 
No. of No. No. of No. 
patients units patients units 
PRBC ~ 
Intraoperative 16 25 23 48 
Postoperativet 7 12 5 11 
Platelets 
Intraoperafive 0 0 2 15 
Postoperative 0 0 0 0 
FFP:~ 
Intraoperative 0 0 1 5 
Postoperative 3 8 1 8 
Cryoprecipitate 
Intraoperative 0 0 1 5 
Postoperative 0 0 2 30 
~Packed red blood cells. 
tFirst 24 hours. 
~Fresh frozen plasma. 
Standard tests of coagulation and Hct were 
obtained at the conclusion of surgery and for 24 
hours after the operation (Fig. 3). The platelet count, 
PT, fibrinogen level, and hematocrit were similar 
between groups on arrival in the recovery room and 
at 8, 16, and 24 hours into the postoperative period. 
PTT was significantly prolonged in patients in the 
saline solution group on arrival in the recovery room 
but thereafter was identical to that in patients in the 
protamine group. 
Blood product requirements were similar for the 
two groups both during and after the surgical 
procedure (Table IV). No differences were seen in 
red blood cell requirement between study groups, 
and only patients in the protamine group undergoing 
AAA required platelets and cryoprecipitate. Intrave- 
nous fluid administration a d urine output were also 
similar in both groups. 
No wound hematomas were noted in any patient 
from either study group during the 3-day postoper- 
ative observation period. One patient who under- 
went IIB in the saline solution group, however, 
required reexploration for excessive postoperative 
bleeding in the first 24 hours after the operation. 
Three patients undergoing lib required reoperation 
for thrombosis of vascular grafts; two of the patients 
were in the protamine group. 
Swan-Ganz catheters were placed in all 40 pa- 
tients undergoing repair of AAA and in 18 of the 49 
patients undergoing IIB. A significant reduction in 
RVEF from a baseline value of 45% was observed for 
patients in the protamine group (EF = 38% -+ 3%) 
relative to patients in the saline solution group 
(EF = 45% + 3%) 6 minutes after study drug 
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Standard Coagulation Test Values and Hematocrit in the Postoperative Period 
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Fig. 3. Standard coagulation i dexes and hematocrit n the first 24 hours after operation. 
Platelet count, PT, fibrinogen level, and hematocrit were similar between saline solution and 
protamine groups on arrival in recovery room and at 8, 16, and 24 hours after operation. PTT 
was prolonged in patients in the saline solution group on arrival to recovery room but was 
similar to values for patients in protamine group thereafter. 
administration (p < 0.05). Ventricular loading con- 
ditions were similar between groups after study drug 
was administered asindicated by identical PCWP and 
RVEDV. Furthermore PAP and MAP were similar 
between patients after exposure to either saline 
solution or protamine. 
DISCUSSION 
Results of this study strongly suggest that prot- 
amine neutralization of heparin may not be routinely 
required during peripheral revascularization pera- 
tions. Total blood loss, perioperative hematocrit, 
blood product use, and the subjective clinical assess- 
ment of coagulation status was similar between 
groups of patients given protamine or saline solution 
to reverse heparin anticoagulation effects. The degree 
of hemostasis was similar between groups in spite of 
a mild prolongation of coagulation tests that are 
sensitive to heparin effect, including ACT and PT f  
during the operation and on arrival to the recovery 
room. This observation agrees with other eports that 
show that coagulation status after vascular or open- 
heart procedures does not require a return to baseline 
to ensure adequate hemostasis. 7,22 
The apparent lack of protamine requirement in 
peripheral vascular surgical procedures i probably 
the result of both heparin dose and heparin metabo- 
lism at normothermia. Heparin levels increased to 
only an average of 0.65 U/ml after the 90 U/kg 
heparin load and progressively decreased throughout 
the procedure, paralleled by reductions in ACT. 
Because heparin levels can vary widely because of 
alterations in metabolism and distribution, prot- 
amine reversal doses in this study were based on 
heparin levels rather than a rigid reversal protocol 
based on heparin dosage. 1,12,1s,23,24 Previous studies 
have confirmed the efficacy of calculating protamine 
reversal doses based on determination of plasma 
heparin levels at the time of reversal rather than 
relying on protamine dosage protocols based on the 
amount of heparin administered or various clotting 
times.iS, 23 
Measured blood loss in this study for the surgical 
procedure was similar between the two groups of 
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patients. However, blood loss was actually higher for 
the period from study drug administration to the end 
of the surgical procedure in patients who received 
protamine. Protamine has been shown to interfere 
with the coagulation cascade, as indicated by 
protamine-induced increases in PT, PTT, and the 
Lee-White Clotting Time. ~1,2s Transient thrombocy- 
topenia and platelet aggregation with release of 
mediators has also been shown to occur after 
protamine administration. 1,8,9,12,~3,26 Excess prot- 
amine is not necessary for deleterious effects on 
platelets, because the heparin-protamine complex has 
also been shown to cause a significant reduction in 
platelet aggregation and decreased platelet sensitivity 
to ADP and epinephrine} ° 
The removal of routine protamine administration 
from peripheral vascular surgical procedures may 
result in a significant reduction in patient morbidity 
and mortality. The toxicity of protamine is well 
established; adverse reactions range from 0.6% to 
27% and vary from mild vasodilatation to anaphy- 
lactic shock and death. 27 Such protamine-induced 
anaphylactic reactions have a 40- to 50-fold greater 
risk of occurrence in diabetic subjects receiving 
protamine-insulin preparations. 17,28 Furthermore 
when adverse reactions to protamine occur, they 
appear to last longer and to be more severe in patients 
who regularly receive protamine-insulin preparations 
as compared with those in nondiabetic patients. 29 
Because diabetes is a disease that predisposes to 
peripheral vascular disease, many patients presenting 
for peripheral vascular surgical procedures can be 
expected to be on insulin-protamine preparations and 
therefore to be at an increased risk for a severe 
reaction to protamine. 
Other mechanisms implicated in protamine- 
associated hemodynamic instability include pulmo- 
nary hypertension from pulmonary vasoconstriction 
caused by thromboxane generation, 3'5,3° systemic 
vasodilatation from histamine release, and direct 
myocardial depression. 2,4,6 Although in this study 
significant differences in MAP and PAP did not 
appear in patients exposed to protamine, the first 
observation point was a full 2 minutes after prot- 
amine was administered. Hypotension from vasodi- 
latation was largely resolved, because hemodynamic 
changes from histamine release are typically transient. 
An improved experimental design would have in- 
cluded documentation of the lowest MAP and 
highest PAP achieved after protamine administra- 
tion. The transient fall in ejection fraction that 
occurred after protamine administration with no 
change in loading conditions uggests that impair- 
ment of contractile function was present, as observed 
by others. 2'31 
Although the low incidence of postoperative 
thrombosis in this study prechldes any definitive 
statement concerning the role of heparin eutraliza- 
tion in postoperative thrombosis, the elimination of 
protamine administration i  peripheral vascular sur- 
gical procedures may be beneficial in maintaining 
patency of vessels during and after operation because 
of a continued heparin effect. This finding is espe- 
cially important, because ahypercoagulable state has 
been observed throughout the perioperative period 
in these patients. 32,33 Animals maintained on heparin 
for a prolonged period after CEA have been shown 
to have improved patency rates. 34 Other animal 
studies have concluded that the administration of 
heparin after CEA prevents thrombus formation. 3s 
Vessel patency was not directly measured in the 
postoperative p riod in this study. Such data would 
have been valuable to determine whether a mild 
coagulopathy induced by residual heparin is helpful 
in preventing early thrombus formation in revascu- 
larized sites. 
Wound hematoma requiring drainage or reop- 
eration was observed in only one ( < 1%) patient in 
this study in a patient in the saline solution group. 
Incidences of wound hematoma after carotid endar- 
terectomy have been reported to range from 1.9% to 
4.3%; postoperative hypertension and chronic pre- 
operative antiplatelet drug usage are considered 
major risk factors for hematoma development. 3638 It 
is evident hat wound hematomas and the need for 
reoperation were not increased by an absence of 
protamine neutralization of residual heparin. 
In summary, protamine does not appear to be 
routinely necessary for heparin neutralization in 
elective peripheral vascular surgical procedures. The 
mild, transient prolongation of coagulation i dexes 
that are sensitive to heparin did not affect blood loss, 
the requirement for blood products, reoperation for 
bleeding, or wound hematoma formation. Because 
protamine can cause a number of significant, delete- 
rious, physiologic alterations, the removal of prot- 
amine from peripheral vascular surgical protocols 
may result in a reduced incidence of hemodynamic 
instability and morbidity. 
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DISCUSSION 
Dr. Eric Endean (Lexington, Ky.). Dr. Elliott and his 
colleagues have presented a prospective randomized study 
in which patients were either given placebo r protamine 
immediately after completion of the vascular anastomosis. 
The primary end points of this study were measurements of 
blood loss, indexes of coagulation, and the need for blood 
product administration. The dose of protamine was 
calculated on the basis of plasma heparin concentrations. 
They found that there were no differences in total blood 
loss, but interestingly blood loss that occurred after the 
study drug was given was greater in the group that received 
protamine. No subjective differences in the amount of 
bleeding, however, were noted by the surgeons, and there 
were no significant differences in the amount of fresh- 
frozen plasma or packed red blood cells administered tothe 
two groups. As expected, plasma heparin concentrations, 
partial thromboplastin times, and activated clotting times 
were significantly different in the patients who received 
protamine than in those who received the placebo. 
The authors' conclusions are that the routine use of 
protamine does not appear to provide clinical benefit and 
may in fact expose patients to potentially serious ide effects 
of protamine. 
Early in my training and in discussions with my 
colleagues, the administration of protamine was almost 
routine during vascular surgery procedures. As we have 
learned more about its potential serious side effects, it has 
been my impression that there has been a trend to use less 
protamine. In our practice at the University of Kentucky, 
we do not routinely use protamine to reverse the effects of 
heparin, especially in patients undergoing carotid endar- 
terectomy or infrainguinal bypass, and this study supports 
my bias. However, I am somewhat concerned if we are 
seeing the pendulum swing too far. Is there a middle 
ground in which the use of protamine is not only desired 
but beneficial? Are there any situations in which the authors 
would recommend the use of protamine or currently use it 
in their practice? I found it interesting that the dose of 
protamine was based on plasma heparin levels. I wonder if 
the authors could describe how plasma heparin levels were 
determined, how" much time it took to obtain the results, 
and if they feel that this led to more or less than needed. I 
would also like to know how much protamine was given 
based on the plasma heparin levels. While total blood loss 
was not different between the study groups, patients who 
received protamine had a greater blood loss noted only after 
the study drug was given. This finding was not correlated 
with the surgeon's ubjective assessment of bleeding. Do 
the authors have an explanation for this finding, specifically 
for the difference in measured blood loss? Finally, while not 
discussed in the presentation but mentioned in the article, 
the authors used the thromboelastograph as another 
measure of clotting. Since this is not a standard coagulation 
test, could the authors elaborate on the usefuhaess of this 
test and its potential place in clinical practice? 
Again, I appreciate the opportunity to open discussion 
of this paper. 
Dr. Bruce M. Elliott. I really do not know when to use 
protamine anymore. The instigating episode for this trial 
was a fatal anaphylactic reaction on the operating table after 
a pedal bypass in a diabetic patient. Since that time, by 
virtue of using the protocol, it retrained me as to what I 
would accept as acceptable hemostasis, with the caveat that 
our aortic reconstructions are performed using collagen- 
impregnated grafts. I have used protamine very rarely since 
the completion of this study. 
Heparin levels were obtained in our anesthesia l bora- 
tory in the operating room. It added about 3 to 4 minutes 
to the time when the surgeon would complete the 
anastomosis and would call for the study drug. This is 
commonplace in cardiac surgery when they obtain their 
heparin concentrations for protamine r versal. It certainly 
did not add any significant length of time to our 
procedures. I would say that it did significantly reduce the 
amount of protamine that we would have arbitrarily given 
before this study. Ordinarily we would have used one-for- 
one reversal, and in fact it cut our protamine dose by half, 
which may be why we did not observe as many profound 
hemodynamic shifts as we would have anticipated. 
Finally, I believe that thromboelastography is prone to 
subjective interpretation and has limited utility in periph- 
eral vascular procedures. 
Dr. G. Patrick Clagett (Dallas, Texas). There is 
something not quite logical, but I think I can explain. You 
have patients with major vascular operations, aortic surgery 
principally, and at the end of the procedure their aPTF is 
abnormally prolonged. It makes sense that they are going 
to continue to bleed. The degree ofhemostatic impairment 
is probably related to the initial heparin dose. For those of 
us who use higher doses ofheparin, up to 100 to 150 U/kg, 
not reversing heparin under those circumstances with a 
large raw wound might be disastrous. I think one has to be 
a little bit careful and one cannot extrapolate your results if 
one uses a higher initial heparinizing dose. 
Dr. Elliott. Absolutely. There are a couple of caveats 
to this. First, the dose of heparin that was given was 90 
U/kg, so the average 70 kg patient would receive 6300 U. 
I expect here are a number of surgeons in this room who 
use an arbitrary dose of 5000 U every time they administer 
heparin to the patient just as there are some who calculate 
a dose at 90 to 100 to 150 U/kg. At the doses we employed 
and using collagen-impregnated grafts for the repair of 
abdominal aortic aneurysms, we found no clinical advan- 
tage for the use of protamine. 
